Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 630 across all filing types
Latest filing 2024-11-08 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
《关于江苏浩欧博生物医药股份有限公司股票交易严重异常波动的询证函》的回函
Regulatory Filings Classification · 95% confidence The document is a formal response letter to an inquiry about unusual stock price fluctuations of Jiangsu Haobo Biomedical Co., Ltd. It states that the controlling shareholder and the actual controller have no undisclosed material information affecting stock price and have not traded shares during the period of abnormal stock price movement. The document is short (973 characters) and serves as a reply to a regulatory inquiry rather than a financial report or announcement of a meeting or vote. It does not contain financial data, management discussion, or detailed disclosures typical of annual or interim reports. It is a regulatory communication related to stock trading compliance and disclosure obligations. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2024-11-08 Chinese
江苏浩欧博生物医药股份有限公司股票交易严重异常波动暨停牌核查的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding a serious abnormal fluctuation in its stock trading price and the subsequent suspension of trading for investigation. It details the stock price movements, the reasons for the trading suspension, the company's internal investigation, and the risks related to a major shareholding transfer agreement. The document includes regulatory references to the Shanghai Stock Exchange rules and provides detailed information about the share transfer agreement and strategic cooperation. It does not contain financial statements or quarterly/annual report data but is a regulatory announcement about stock trading abnormalities and related corporate actions. The document length is 4375 characters, which is relatively short and focused on the announcement of the trading suspension and investigation rather than a full financial report or earnings release. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-11-08 Chinese
江苏浩欧博生物医药股份有限公司2024年第一次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as "2024 年第一次临时股东大会会议资料" which translates to "2024 First Extraordinary General Meeting (EGM) Meeting Materials". It contains detailed meeting agenda, voting procedures, and multiple proposals (议案) to be discussed and voted on at the meeting. The content includes shareholder meeting instructions, agenda, and detailed proposals related to waivers of voluntary share lock-up commitments by directors and senior management, strategic cooperation agreements, and related party transactions. The document is clearly a set of materials prepared for a shareholders' meeting, specifically an extraordinary general meeting, rather than a report or announcement of results. It is not an annual report, earnings release, or regulatory filing. It is not a proxy solicitation or voting results announcement but the actual meeting materials. Therefore, the document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during general meetings (including extraordinary meetings). The length and detail confirm it is the meeting materials, not just an announcement or notice.
2024-11-07 Chinese
江苏浩欧博生物医药股份有限公司股票交易异常波动暨严重异常波动公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the abnormal and severe abnormal fluctuations in the stock price of Jiangsu Haoubo Biopharmaceutical Co., Ltd. It details the stock price movements, the company's investigation into the causes, related share transfer agreements, strategic cooperation, and risk warnings to investors. The document does not contain comprehensive financial statements or detailed financial performance data typical of an Annual Report or Interim Report. It is primarily a regulatory disclosure about stock price volatility and related corporate actions, consistent with regulatory filing requirements for stock exchanges. The document length is 4010 characters, which is relatively short and focused on a specific event rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-11-07 Chinese
《关于江苏浩欧博生物医药股份有限公司股票交易异常波动暨严重异常波动的询证函》的回函
Regulatory Filings Classification · 95% confidence The document is a formal response letter addressing inquiries about abnormal stock price fluctuations and confirms that no undisclosed major information or insider trading occurred during the period of abnormal trading. It does not contain financial statements, management discussion, or detailed financial data. It is a regulatory communication related to stock trading behavior and compliance, rather than a financial report or announcement of a corporate event like a merger or capital change. The document length is short (1218 characters) and it serves as a reply to a regulatory inquiry, fitting best under general regulatory filings rather than any specific financial report or announcement category.
2024-11-07 Chinese
江苏浩欧博生物医药股份有限公司股票交易风险提示公告
Regulatory Filings Classification · 95% confidence The document is a stock trading risk warning announcement issued by the company's board, highlighting abnormal stock price fluctuations, risks related to a major share transfer agreement, and other investment risks. It includes no financial statements or detailed financial analysis but focuses on market risk, shareholding changes, and regulatory compliance disclosures. The document length is 3177 characters, which is relatively short and consistent with a regulatory announcement rather than a full financial report. It does not contain quarterly or annual financial results, nor is it a certification or proxy material. The content aligns with a Regulatory Filing (RNS) as it is a formal disclosure about stock trading risks and shareholding changes without being a full report or a voting result announcement.
2024-11-06 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.